Company intelligence / Profile preview

Bonum Therapeutics

Ownership: Private
Employees: ~33
Development stage: Preclinical

Overview

All current programs are preclinical. The company is advancing regulated cytokine therapies for oncology and other indications. No human clinical results have been reported as of early 2025.[10]

Therapeutic areas: OncologyImmunologyNeurologyMetabolic Disorders
Modalities: Protein therapeutics (regulated cytokines)Antibody-based therapeuticsImmunocytokines (antibody-cytokine fusion proteins)Large molecules[1][6][9]
Industry: Biotech

Drug pipeline

7 assets

ATP-IL12

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

Roche Venture Fund (investor)seeking additional pharma/biotech collaborations but none announced as of May 2025.[6][9]

Beyond the preview

Go deeper on Bonum Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bonum Therapeutics.

Explore the full profile